Morphometric Markers of the Effectiveness of Micropulse Cyclophotocoagulation
ConditionGlaucoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKazakh Eye Research Institute
About this trial
This prospective study aims to evaluate morphometric markers of treatment response following micropulse transscleral cyclophotocoagulation (MP-CPC) in patients with glaucoma. The study will assess changes in choroidal thickness and the choroidal vascularity index (CVI) measured by optical coherence tomography (OCT) before treatment, 3-7 days after the procedure, and 1 month postoperatively.
Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in choroidal thickness, the choroidal vascularity index (CVI) and IOP reduction will be analyzed. Additionally, the study seeks to determine the minimal baseline choroidal thickness associated with a clinically significant hypotensive effect after MP-CPC.
Eligibility criteria
Qualifiers
Decision to treat by MP-CPC Laser
Patients diagnosed with Glaucoma
Patients aged 18 years old and above
Glaucoma that is inadequately controlled on medical therapy
Disqualifiers
Patients age less than 18 years
Patients unable or unwilling to provide informed consent to participate in the study
Patients potentially unavailable for follow up visits
Patients with significant scleral thinning
Trial design
Treatments tested in this trial
- MicroPulse transscleral cyclophotocoagulation
- Conventional transscleral cyclophotocoagulation
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov